Testosterone injection

DRUG6 trials

Sponsors

Queen's University, The University of Texas Medical Branch, Galveston, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Oregon Health and Science University, Parc de Salut Mar

Conditions

AIDSHIVHealth Services for Transgender PersonsHealthyHealthy VolunteersHyperlipidemiaLipodystrophyProstate Cancer

Early Phase 1

Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents

CompletedNCT03864913

Oregon Health and Science UniversityHealth Services for Transgender Persons, Transgender Persons

Start: 2018-01-26End: 2019-12-30Updated: 2024-04-03

Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

CompletedNCT06393634

Sports Medicine Research and Testing LaboratoryHealthy

Start: 2024-11-27End: 2024-11-27Updated: 2024-12-03

Phase 1

Generation of Biological Samples Positive to Testosterone for Anti-doping Control

CompletedNCT04207684

Parc de Salut MarHealthy Volunteers

Start: 2020-02-04End: 2020-02-26Updated: 2020-07-17

Phase 4

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

CompletedNCT00957801

The University of Texas Medical Branch, GalvestonSarcopenia

Start: 2009-03-31End: 2015-12-31Updated: 2018-05-08

Unknown Phase

The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS

CompletedNCT00202241

Queen's UniversityAIDS, HIV, Hyperlipidemia +1

Start: 1999-09-30End: 2001-06-30Target: 30Updated: 2016-01-13

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

CompletedNCT01084759

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer

Start: 2010-03-31End: 2014-10-31Updated: 2016-05-09

Related Papers

A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2014-05-20

A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2014-02-011 citations